Get the Stockscreener App
95.70
0.76%
-0.73
After Hours:
95.70
Celcuity Inc stock is traded at $95.70, with a volume of 515.51K.
It is down -0.76% in the last 24 hours and up +3.47% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$96.43
Open:
$95.83
24h Volume:
515.51K
Relative Volume:
0.35
Market Cap:
$4.68B
Revenue:
-
Net Income/Loss:
$-192.89M
P/E Ratio:
-24.55
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
+8.21%
1M Performance:
+3.47%
6M Performance:
-14.69%
1Y Performance:
+75.69%
1-Day Range:
$94.55
$97.25
1-Week Range:
$86.99
$98.00
52-Week Range:
$44.42
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
95.70 | 4.43B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
Getting To A First Product Approval With Celcuity's Brian Sullivan｜Business Of Biotech - finance.biggo.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com South Africa
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - The National Law Review
Brian Sullivan: The $20 Million Bet That Resurrected Pfizer's Shelved Cancer Drug - finance.biggo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen - MarketBeat
Needham cuts Celcuity stock price target on updated revenue model By Investing.com - Investing.com Australia
Celcuity Stock Price Forecast. Should You Buy CELC? - StockInvest.us
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Celcuity (CELC) Q2 2026 Ergebniskonferenz: REVTORPYK-Markteinführung für Ende Q3 geplant - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call: REVTORPYK Launch Set for Late Q3 - TradingKey
Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings - MarketBeat
Celcuity remains a Buy as FDA approval and stro... - Pluang
Stifel cuts Celcuity stock price target on refined market model - Investing.com
Stifel cuts Celcuity stock price target on refined market model By Investing.com - Investing.com Australia
Celcuity (NASDAQ:CELC) Given New $140.00 Price Target at Needham & Company LLC - MarketBeat
Celcuity: REVTORPYK Is Now A Commercial Story (NASDAQ:CELC) - Seeking Alpha
Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at Stifel Nicolaus - MarketBeat
Celcuity Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Celcuity Analysts Slash Their Forecasts After Q2 Loss - Benzinga
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside - TradingView
Needham cuts Celcuity stock price target on updated revenue model - Investing.com
Celcuity Inc. Stock 12‑Month Price Target Cut to $162.18, Implies 87% Upside - TradingView
Celcuity Q2 Net Loss Widens to $73.6M as R&D Spending Rises - minichart.com.sg
CELC|Celcuity Inc|Price:91.810|Chg%:-0.190 - TradingKey
CELC SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
CELCUITY INC. : JEFFERIES RAISES TARGET PRICE TO $163 FROM $153 - Moomoo
Celcuity Q2 Adjusted Loss Widens - Moomoo
Celcuity Q2 2026 Earnings Call Transcript - MarketBeat
CELC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Celcuity Inc. - ACCESS Newswire
CELCUITY INC. : NEEDHAM CUTS TARGET PRICE TO $140 FROM $157 - Bitget
Celcuity Q2 Earnings Call Highlights - MarketBeat
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):